Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AUT1
- Development stage
- Preclinical
- Lead developer
- Autifony Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AUT1 (also known as RE01) is a first-generation, small-molecule positive allosteric modulator (PAM) of the voltage-gated potassium channel subtypes Kv3.1 and Kv3.2 (specifically Kv3.1b and Kv3.2a). Developed by Autifony Therapeutics, AUT1 acts by shifting the voltage-dependence of channel activation toward more hyperpolarized potentials, thereby facilitating channel opening and enhancing the high-frequency firing fidelity of fast-spiking parvalbumin-positive (PV+) GABAergic interneurons. It has been widely utilized as a preclinical research tool to investigate the therapeutic potential of Kv3 channel modulation in central nervous system disorders. Preclinical studies have demonstrated its efficacy in animal models of schizophrenia (reversing cognitive deficits), bipolar disorder/mania (reducing amphetamine-induced hyperactivity), and Alzheimer's disease (rescuing deficits in interneuron firing and gamma-oscillations).
- Other names
- (5R)-5-ethyl-3-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)-2,4-imidazolidinedioneAUT 1AUT1AUT-1
02
Targets
KCNC1 (Kv3.1)KCNC2 (Potassium voltage-gated channel subfamily C member 2)
Beyond the preview
Go deeper on AUT1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AUT1.